18 February 2024 in Respirology
13 December 2024 in Chest
11 July 2025 in Current Opinion in Pulmonary Medicine
Purpose of review: This review describes the properties and examines available evidence supporting LUS as a screening tool for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). ILD is a common and serious complication of RA, associated with high mortality rates, especially when diagnosed late. Despite its high prevalence and significant prognostic impact, the need for and approach to systematic screening for lung involvement in RA remain unclear and are not recommended in current guidelines. While high-resolution computed tomography (HRCT) is the gold standard for diagnosing ILD, it cannot be frequently repeated due to limitations in the availability, cost, and radiation exposure. Recent findings: Lung ultrasound (LUS) has emerged as a potential noninvasive, accurate, low-cost, and nonionizing alternative for detecting ILD, offering high sensitivity and negative-predictive value (NPV) compared to HRCT. Key LUS findings indicative of ILD include B-line artefacts (BLA) and pleural irregularity. Evidence supporting the performance and applicability of LUS in diagnosing RA-ILD continues to grow. Summary: LUS has shown a good performance in ILD detection. Further research and standardization efforts are needed to fully integrate LUS into routine RA screening protocols.
14 September 2024 in European Respiratory Journal
The screening strategy for interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients without respiratory symptoms is still a subject of debate. This study aimed to assess the performance of lung ultrasonography (LUS) as a screening tool for RA-ILD and compare it with spirometry and DLCO. Methods: A multinational cross-sectional study conducted between June and December 2023 enrolled consecutively selected RA patients aged 17 or older without respiratory symptoms from Argentina, Greece, France, and Mexico. High-resolution Computed Tomography (HRCT) served as the gold standard for ILD diagnosis, performed within 30 days of LUS and pulmonary function tests. Investigators, blinded to HRCT results and clinical data, conducted LUS by exploring 14 areas, considering it positive when the sum of B lines was ≥ 5. Results: Of the 199 patients (78.9% women, median age 63, 52-70 years), with a median time from RA diagnosis to study inclusion of 10 (4-18) years, 48% were past or current smokers, and 76% were seropositive. A total of 53 (26.6%; 95% CI: 20.6-33.3) patients had HRCT-confirmed ILD diagnosis. The negative predictive value of LUS was 93% (87%-97%). The performance of other diagnostic tests is detailed in the table. Conclusions: In 93 out of 100 RA patients without respiratory symptoms, ILD could be ruled out with LUS, proving to be an accurate diagnosic tool for ILD screening. erj;64/suppl_68/OA3785/F1 F1 F1
9 September 2023 in European Respiratory Journal
It is still controversial how to screen for interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). We aimed to evaluate the performance of lung ultrasonography (LUS) as screening tool of RA-associated interstitial lung disease (ILD), and to compare it with that of the physical exam, chest X-ray, and pulmonary function tests (PFTs). Methods: cross-sectional study of consecutive patients with RA evaluated by the rheumatology clinic of the Institute of Psychophysical Rehabilitation of Buenos Aires (Argentina), from January to December 2022. High resolution Computed Tomography (HRCT) was the gold standard for ILD diagnosis, and it was performed within 30 days of the LUS, the respiratory evaluation and the PFTs. Investigators were blinded to HRCT results and patients´ clinical data. LUS was performed by exploring 14 areas, and assumed as positive when the sum of B lines was ≥ 5. Results: 105 patients were included, 86 (81,9%) were women, median age 62 (55-68) years. The median RA disease duration at inclusion was 14 (8-24) years. A total of 32 patients (30,5%, 95% CI: 22% - 40%) had ILD. The negative predictive value (NPV) of LUS for ILD diagnosis was 95% (85%-99%). The results of the rest of the diagnostic variables for each test are shown in figure 1. Conclusions: Given the high negative predictive value, LUS is a useful tool to rule-out ILD in patients with RA in rheumatology clinic.